

CORRIGENDUM

Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

C. Marth, F. Landoni, S. Mahner, M. McCormack, A. Gonzalez-Martin & N. Colombo, on behalf of the ESMO Guidelines Committee

Ann Oncol 2017; 28: iv72–iv83 (doi:10.1093/annonc/mdx220)

Under the section “Adjuvant treatment”

Adjuvant treatment

Women with risk factors on the pathology specimen should receive adjuvant therapy following hysterectomy (Table 3). Two classes of risk are defined: intermediate- and high-risk patients.

Is replaced with:

Adjuvant treatment (Table 3)

Two classes of risk are defined: intermediate- and high-risk patients.

In “Table 5. Summary of recommendations”

Adjuvant treatment

- Women with intermediate- and high-risk factors on the pathology specimen should receive adjuvant therapy following hysterectomy (see Table 3).
- Cervical cancer patients with intermediate-risk disease do not need further adjuvant therapy [II, B], whereas adjuvant CRT is recommended in high-risk patients [I, A].

Is replaced with:

Adjuvant treatment

- Cervical cancer patients with intermediate-risk disease do not need further adjuvant therapy [II, B], whereas adjuvant CRT is recommended in high-risk patients [I, A].